| Annual · values | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | 7.63% | 29.80% | 28.32% | 21.98% | -1.21% | 4.62% | 88.15% | — | — |
| Operating Margin | — | -369.56% | -1165.64% | -245.86% | -635.08% | -903.93% | -1253.13% | -488.46% | -359.88% | 12.48% | — | — |
| EBITDA Margin | — | -356.22% | -1149.98% | -236.62% | -612.67% | -881.08% | -1220.36% | -454.99% | -343.02% | 12.48% | — | — |
| Net Margin | — | -592.72% | -1236.18% | -333.61% | -653.54% | -920.29% | -1168.60% | -515.42% | -375.82% | 9.02% | — | — |
| Current Ratio | 0.11 | 0.23 | 0.13 | 0.66 | 0.30 | 0.50 | 0.55 | 3.18 | 0.60 | 23.12 | 0.03 | — |
| Quick Ratio | 0.11 | 0.23 | 0.13 | 0.66 | 0.30 | 0.50 | 0.55 | 3.16 | 0.60 | 23.12 | 0.03 | — |
| Debt / Equity | — | — | 0.14 | — | 0.97 | — | — | — | — | — | — | — |
| ROE | -197.84% | -111.27% | -226.73% | -106.92% | -294.73% | -307.98% | -404.70% | -71.55% | -55.41% | 1.57% | 231.87% | — |
| ROA | -78.04% | -37.66% | -81.17% | -60.40% | -88.76% | -122.31% | -172.25% | -60.11% | -31.96% | 1.50% | -15982.47% | — |
| Asset Turnover | 0.00 | 0.06 | 0.07 | 0.18 | 0.14 | 0.13 | 0.15 | 0.12 | 0.09 | 0.17 | — | — |
| Book Value / Share | 2.87 | 7.58 | 0.70 | 1.20 | 0.36 | 0.05 | 0.06 | 0.16 | 0.11 | 0.07 | — | — |
Avalon GloboCare Corp. is a commercial-stage company focused on developing and delivering precision diagnostic consumer products, advancing cellular therapy intellectual property, and owning commercial real estate properties in the United States. It markets the KetoAir™ breathalyzer, a handheld nanosensor device that measures breath acetone levels to monitor ketosis and fat metabolism, integrated into wellness programs for first responders and ketogenic health management. The company distributes KetoAir™ through wholesale agreements, affiliate programs, and online channels in the United States and United Kingdom, while co-developing additional applications like a cannabis breathalyzer for point-of-care detection. Avalon GloboCare Corp. advances proprietary CAR-T and CAR-NK cell technologies, including bispecific designs and cytokine induction methods protected by patents in multiple jurisdictions. Through subsidiaries like Avalon Quantum AI, LLC and Q&A Distribution, LLC, it operates generative AI software for nutrition and publishing, alongside real estate operations. Founded in 2015 and headquartered in Freehold, New Jersey, Avalon GloboCare Corp. plays a role in the intersection of diagnostics, biotech IP, AI-enabled health tools, and property management within healthcare and real estate markets.